Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...
The current probability surface calculates a 10-Day Densest High ceiling of $50 and a Densest Low floor of $0.
Unlock VKTX 200-Day Probability Cloud ($4/mo)